Related Experiment Video
Updated: Aug 11, 2026
07:56
Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Decreased bone mineral density in children with phenylketonuria
J R Allen1, I R Humphries, D L Waters
1James Fairfax Institute of Paediatric Clinical Nutrition, Children's Hospital, Camperdown, New South Wales, Australia.
The American Journal of Clinical Nutrition
|February 1, 1994
Summary
Children with phenylketonuria (PKU) exhibit reduced bone mineralization, specifically lower total body and spine bone mineral density (BMD). This occurs despite adequate dietary intake of key minerals, indicating a complex issue requiring further investigation.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Bone Health
Background:
- Previous research indicates potential bone mineralization deficits in children with phenylketonuria (PKU).
- Understanding bone health in PKU is crucial for long-term patient outcomes.
Purpose of the Study:
- To investigate and quantify bone mineral density (BMD) in prepubertal children with PKU.
- To compare BMD between children with PKU and age-matched controls.
- To assess the influence of dietary intake on bone mass in this population.
Main Methods:
- Bone mineral density (BMD) of the total body (TBMD) and spine (SBMD) was measured using dual-energy X-ray absorptiometry (DXA).
- Measurements were taken in 32 prepubertal children with PKU and 95 control subjects.
- Dietary intake of calcium, phosphorus, and magnesium was assessed in subsets of participants.
Main Results:
- Children with PKU showed significantly lower TBMD and SBMD compared to control subjects, even after adjusting for height and weight.
- The PKU group had a higher intake of calcium, phosphorus, and magnesium than controls.
- Lower BMD in PKU children occurred despite adequate dietary intake based on current recommendations.
Conclusions:
- Prepubertal children with PKU have reduced bone mineral density.
- The observed deficit in bone mass is not explained by inadequate dietary intake of key minerals.
- Further research is necessary to determine the underlying causes and potential nutritional interventions for low BMD in PKU.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:21Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...